非霍奇金淋巴瘤 (NHL) 具有异质性，是全世界最常见的血液恶性肿瘤之一。尽管 NHL 患者的治疗取得了进展，但预计一些患者会出现复发或对治疗产生耐药性。因此，需要新的治疗方法。最近，基于自然杀伤 (NK) 细胞的免疫疗法单独或与单克隆抗体、嵌合抗原受体或双特异性杀伤接合剂组合已应用于 NHL 治疗的许多研究中。 NHL 肿瘤微环境中 NK 细胞的功能缺陷和癌细胞逃避 NK 细胞介导的细胞毒性的能力，以及之前在 NHL 中基于 NK 细胞的免疫治疗方面的研究的有益结果，引起了我们的关注对于这种治疗策略。本综述旨在总结重点关注 NK 细胞在 NHL 患者免疫治疗中应用的临床研究。© 2024。作者。

Non-Hodgkin lymphomas (NHLs) are heterogeneous and are among the most common hematological malignancies worldwide. Despite the advances in the treatment of patients with NHLs, relapse or resistance to treatment is anticipated in several patients. Therefore, novel therapeutic approaches are needed. Recently, natural killer (NK) cell-based immunotherapy alone or in combination with monoclonal antibodies, chimeric antigen receptors, or bispecific killer engagers have been applied in many investigations for NHL treatment. The functional defects of NK cells and the ability of cancerous cells to escape NK cell-mediated cytotoxicity within the tumor microenvironment of NHLs, as well as the beneficial results from previous studies in the context of NK cell-based immunotherapy in NHLs, direct our attention to this therapeutic strategy. This review aims to summarize clinical studies focusing on the applications of NK cells in the immunotherapy of patients with NHL.© 2024. The Author(s).